Q1 2026 delivered continued EBITDA profitability despite a 16% revenue decline, mainly due to lower BD shipments and timing effects. Strategic partnerships advanced, with BD launching coated Foley catheters in Europe and Zimmer Biomet transitioning to a new business setup.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.